Overall, it is clear that FXR agonists in cholestasis act by directly transactivating genes such as ABCB11, but our data adds to regulatory complexity of this process as FXR agonists also act by blocking an inhibitory pathway mediated by miR-199a-5p. Here, NR1H4 is linked to cholestasis.